Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( (DE:2TZ) ) has shared an announcement.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited held its second board meeting for FY2025, where it approved the disposal of its remaining 12% equity interest in Tianjin TSKF Pharmaceutical Co., Ltd. The equity will be transferred to Haleon China Co., Ltd. and Haleon CH SARL for a total consideration of approximately RMB1.62 billion. This strategic move will result in the company ceasing to hold any equity in the target company, potentially impacting its market positioning. Additionally, the company plans to convene its first extraordinary general meeting in 2025 to seek shareholder approval for this disposal.
More about Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, formerly known as Tianjin Zhongxin Pharmaceutical Group Corporation Limited, is a company incorporated in the People’s Republic of China. The company operates in the pharmaceutical industry and is involved in the production and distribution of pharmaceutical products.
YTD Price Performance: -7.58%
Technical Sentiment Signal: Sell
Current Market Cap: €3.19B
Find detailed analytics on 2TZ stock on TipRanks’ Stock Analysis page.